Cobra Biologics and KAHR Medical Limited will continue their partnership. The move will allow Cobra to advance both KAHR-101 and KAHR -102 for future preclinical and clinical testing using its maxXpress service. MaxXpress enable rapid clone selection and production by combining UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team. Cobra Biologics will also carry out the process development and scale up for GMP production of both KAH...